[{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Moxidectin","moa":"Gamma-aminobutyric acid receptor (GAR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicines Development for Global Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicines Development for Global Health \/ Undisclosed"},{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Moxidectin","moa":"Gamma-aminobutyric acid receptor (GAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicines Development for Global Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medicines Development for Global Health \/ Undisclosed"},{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"AMG 634","moa":"PDE4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines Development for Global Health \/ Medicines Development for Global Health","highestDevelopmentStatusID":"8","companyTruncated":"Medicines Development for Global Health \/ Medicines Development for Global Health"}]

Find Clinical Drug Pipeline Developments & Deals by Medicines Development for Global Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Scabies.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 25, 2023

                          Lead Product(s) : Moxidectin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Amgen will continue to support the two Phase 2 clinical trials in ENL and TB set to begin in 2021 by providing study drug to both studies and funding the ENL study. This support will help ensure a seamless transition in development to MDGH.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 22, 2020

                          Lead Product(s) : AMG 634

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Amgen Inc

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          BioJapan
                          Not Confirmed
                          BioJapan
                          Not Confirmed

                          Details : Moxidectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Onchocerciasis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 17, 2020

                          Lead Product(s) : Moxidectin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank